1IIL

CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.259 
  • R-Value Work: 0.237 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.

Ibrahimi, O.A.Eliseenkova, A.V.Plotnikov, A.N.Yu, K.Ornitz, D.M.Mohammadi, M.

(2001) Proc.Natl.Acad.Sci.USA 98: 7182-7187

  • DOI: 10.1073/pnas.121183798
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Apert syndrome (AS) is characterized by craniosynostosis (premature fusion of cranial sutures) and severe syndactyly of the hands and feet. Two activating mutations, Ser-252 --> Trp and Pro-253 --> Arg, in fibroblast growth factor receptor 2 (FGFR2) ...

    Apert syndrome (AS) is characterized by craniosynostosis (premature fusion of cranial sutures) and severe syndactyly of the hands and feet. Two activating mutations, Ser-252 --> Trp and Pro-253 --> Arg, in fibroblast growth factor receptor 2 (FGFR2) account for nearly all known cases of AS. To elucidate the mechanism by which these substitutions cause AS, we determined the crystal structures of these two FGFR2 mutants in complex with fibroblast growth factor 2 (FGF2). These structures demonstrate that both mutations introduce additional interactions between FGFR2 and FGF2, thereby augmenting FGFR2-FGF2 affinity. Moreover, based on these structures and sequence alignment of the FGF family, we propose that the Pro-253 --> Arg mutation will indiscriminately increase the affinity of FGFR2 toward any FGF. In contrast, the Ser-252 --> Trp mutation will selectively enhance the affinity of FGFR2 toward a limited subset of FGFs. These predictions are consistent with previous biochemical data describing the effects of AS mutations on FGF binding. Alterations in FGFR2 ligand affinity and specificity may allow inappropriate autocrine or paracrine activation of FGFR2. Furthermore, the distinct gain-of-function interactions observed in each crystal structure provide a model to explain the phenotypic variability among AS patients.


    Organizational Affiliation

    Department of Pharmacology, New York University School of Medicine, New York, NY 10016, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
HEPARIN-BINDING GROWTH FACTOR 2
A, B, C, D
155Homo sapiensMutation(s): 2 
Gene Names: FGF2 (FGFB)
Find proteins for P09038 (Homo sapiens)
Go to Gene View: FGF2
Go to UniProtKB:  P09038
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
FIBROBLAST GROWTH FACTOR RECEPTOR 2
E, F, G, H
220Homo sapiensMutation(s): 1 
Gene Names: FGFR2 (BEK, KGFR, KSAM)
EC: 2.7.10.1
Find proteins for P21802 (Homo sapiens)
Go to Gene View: FGFR2
Go to UniProtKB:  P21802
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.259 
  • R-Value Work: 0.237 
  • Space Group: P 1
Unit Cell:
Length (Å)Angle (°)
a = 70.796α = 90.01
b = 72.490β = 89.82
c = 89.919γ = 90.00
Software Package:
Software NamePurpose
CNSrefinement
DENZOdata reduction
AMoREphasing
SCALEPACKdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2001-05-09
    Type: Initial release
  • Version 1.1: 2008-04-27
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance